Date & Time
Monday, October 24, 2022, 10:30 AM - 11:45 AM
401 Prostate Cancer Update for Corrections*

Prostate cancer is the most common malignancy encountered in corrections. While screening guidelines are well standardized, therapy options have become increasingly more complicated. The role of new therapeutics, including hormonal options and novel radiopharmaceuticals, will be discussed, along with their effect on physicians' treatment decisions and patient outcomes.

Educational Objectives

  • Define patients appropriate for PSA screening
  • Review treatment options for patients with low, intermediate, and high-risk prostate cancer
  • Discuss the role of new hormonal and theranostic agents in diagnosis and treatment of prostate cancer

Level Intermediate